Merck and Glenmark Pharmaceuticals settled claims for $573 million over allegations of delaying a generic version of the cholesterol drug Zetia.
Merck reported in its first quarter financial results on Thursday that it incurred a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation, which impacted its earnings per share for the quarter.
Health insurers and pharmacies have filed a lawsuit against Merck and Glenmark, alleging that the companies made an anti-competitive agreement that breached antitrust laws.
Read more: Merck, Glenmark Must Face Antitrust Trial Over Drug Pricing
Glenmark Pharmaceuticals and US pharma giant Merck faced an antitrust lawsuit over allegations that the duo illegally settled a patent dispute in order to delay the launch of generic versions of the blockbuster cholesterol reducer Zetia.
As the owner of a patent for ezetimibe, Merck had sued Glenmark for patent infringement in 2009 in connection with Glenmark’s application to the US Food and Drug Administration (FDA) for approval of a generic version of ezetimibe. Merck also sued Mylan for patent infringement the same year in connection with the US FDA’s approval of a generic version of Vytorin, another Merck proprietary drug containing ezetimibe.
In 2010, Merck and Glenmark signed a written settlement agreement, which was approved by the court, providing, inter alia, that Glenmark would be permitted to market a generic version of Zetia beginning 2016.
Featured News
French Competition Watchdog Raids EPC Groupe
May 20, 2024 by
CPI
Nippon Steel Vice Chairman to Visit US for Key Meetings in U.S. Steel Acquisition
May 20, 2024 by
CPI
Google Pays Damages to US Government in Attempt to Avoid Jury Trial in Antitrust Case
May 20, 2024 by
CPI
Nature’s Miracle and Agrify Terminate Merger Agreement Amid Challenges
May 20, 2024 by
CPI
UK’s AI Safety Institute to Open US Office Amid Growing Calls for Global Collaboration
May 20, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI